EUVIMEDEUVIMED entdecken
Open Access · CC BY-SA 4.0

Manufacturing platforms for vaccines and biologic drugs in resource-limited settings: Challenges, innovations, and pathways to sustainable access

Courage Chandipwisa, Nyaradzo Ellen Masango, Ally Omary Killo, Tendai Pride Zenda, Muhydeen Opeyemi Olojo, Agness Shimilimo

Annales Academiae Medicae Silesiensis · 17.08.2026

DOI: 10.18794/aams/225382 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annales Academiae Medicae Silesiensis, online erschienen am 17.08.2026. Verfasst von Courage Chandipwisa und 5 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Demand for vaccines and biologics continues to rise across human and veterinary health, yet low-resource settings such as Africa carry a disproportionate burden of human immunodeficiency virus, hepatitis B, malaria, tuberculosis, and neglected tropical diseases. This review evaluates manufacturing technologies and strategies that can strengthen local production capacity to improve biologic access, pandemic preparedness, and outbreak response. Methodology A structured narrative review was conducted, guided by the SANRA framework, using peer-reviewed literature published between 2015 and 2026 and retrieved from PubMed/Medline, Scopus, Web of Science, and Google Scholar, supplemented by relevant grey literature on biologics manufacturing in low-resource settings.

Results

No single platform is universally optimal; selection should be matched to local capacity, target disease, and sustainability. Egg-based and cell-culture systems are accessible but limited in speed and scalability, while mRNA platforms adapt fastest yet depend on cold-chain and reagent infrastructure rarely available locally. Recombinant protein and virus-like particle platforms emerged as the most pragmatic compromise, combining thermostability with feasible bioprocessing. Across platforms, sustainable production depended less on the technology than on cross-cutting enablers: modular and single-use manufacturing, digital process control, regulatory harmonisation and World Health Organization prequalification, workforce development, and blended financing. Africa’s approximately 1% share of global vaccine supply underscores that equitable access requires these enablers to advance in coordination.

Conclusions

Meeting the growing need for biologics requires capacity building, infrastructure investment, public-private partnerships, and dedicated funding reducing import dependence and improving pandemic readiness, as the coronavirus disease 2019 pandemic made clear.

Zitieren

APA

Chandipwisa, C., Masango, N. E., Killo, A. O., Zenda, T. P., Olojo, M. O., & Shimilimo, A. (2026). Manufacturing platforms for vaccines and biologic drugs in resource-limited settings: Challenges, innovations, and pathways to sustainable access. Annales Academiae Medicae Silesiensis. https://doi.org/10.18794/aams/225382

Vancouver

Chandipwisa C, Masango NE, Killo AO, Zenda TP, Olojo MO, Shimilimo A. Manufacturing platforms for vaccines and biologic drugs in resource-limited settings: Challenges, innovations, and pathways to sustainable access. Annales Academiae Medicae Silesiensis. 2026. doi:10.18794/aams/225382

BibTeX
@article{Chandipwisa2026,
  author = {Chandipwisa, Courage and Masango, Nyaradzo Ellen and Killo, Ally Omary and Zenda, Tendai Pride and Olojo, Muhydeen Opeyemi and Shimilimo, Agness},
  title = {Manufacturing platforms for vaccines and biologic drugs in resource-limited settings: Challenges, innovations, and pathways to sustainable access},
  journal = {Annales Academiae Medicae Silesiensis},
  year = {2026},
  doi = {10.18794/aams/225382}
}
Kostenlos starten →